Showcasing Updated Clinical Profile & Sustained Overall Survival Benefit of Belantamab Mafodotin Combination to Understand How ADC MoA Translates to Advancing to Earlier Line Oncology Treatments
- Breaking down the updated clinical profile of belantamab mafodotin combinations from DREAMM-7 trial with sustained overall survival benefit in patients with relapsed or refractory multiple myeloma
- Explaining how multi-modal mechanism of action across payload, immunogenic cell death, and adaptive immune response translates to durable patient response and long-term clinical benefit
- Contextualizing belantamab mafodotin’s ongoing regulatory journey
- Evaluating the journey of ADCs transitioning to earlier-line treatments for oncology patients across tumor types